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Abstract
Thyroid associated ophthalmopathy, or thyroid eye disease (TED), is a complex inflammatory disorder of the eye that, as its name implies,
is usually associated with thyroid disease. Clinical observation supports the existence of three main TED subtypes, namely ocular myopa-
thy, congestive myopathy, and mixed congestive and myopathic ophthalmopathy. Although the precise pathophysiology of TED remains
unclear, it is likely to reflect an autoimmune reaction involving sensitised T lymphocytes and autoantibodies directed against a specific
orbital or thyroid-and-orbital shared antigen(s). One well-studied candidate in this immune reaction is the thyroid-stimulating hormone
receptor (TSHR), which is also expressed in the orbital fibroblast and preadipocyte. Most patients with ophthalmopathy have associated
Graves’ disease, 10% have Hashimoto’s thyroiditis in which the eye changes are often mild and expressed mainly as upper eyelid retrac-
tion (UER), and 10% have no apparent associated thyroid disease — so-called “euthyroid Graves’ disease”. Ophthalmopathy can also
occur in some patients with transient thyroiditis, thyroid cancer, and Graves’ disease many years after treatment of the hyperthyroidism
— situations where TSHR antibodies are not expected to be present, suggesting that the relationship between TSHR antibodies and the
eye disorder has not been established for all cases. In our studies of TED we have investigated the nature and significance of antibodies
targeting other eye muscle and orbital connective tissue (OCT) antigens, in particular the calcium binding protein calsequestrin (CASQ1)
and the orbital fibroblast membrane antigen collagen XIII. Our working hypotheses for the pathogenesis of TED are: i) the initial reaction
in the orbit is antibody and T lymphocyte targeting of the TSHR in the OCT compartment, and ii) the associated extra ocular and upper
eyelid muscle inflammation reflects either autoimmunity against primary skeletal muscle antigens such as CASQ1 or a secondary, non
specific effect of the OCT reactions as proposed by the main proponents of the “TSHR hypothesis”. Here, we review the evidence that
autoimmunity against the TSHR expressed in the orbit can be implicated in the development of all cases of TED. Although there is a close
general correlation between ophthalmopathy and TSHR antibodies there are many exceptions, suggesting that the continued study of the
possible role of autoimmunity against calsequestrin and collagen XIII is justified. (Pol J Endocrinol 2010; 61 (2): 222–227)
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Streszczenie
Orbitopatia tarczycowa lub tarczycowa choroba oczu (TED, thyroid eye disease) jest złożoną chorobą zapalną oka i jak nazwa wskazuje
zwykle towarzyszy chorobom tarczycy. Obserwacje kliniczne potwierdzają istnienie trzech głównych podtypów TED: miopatia oczna,
miopatia zastoinowa i mieszana orbitopatia zastoinowa i miopatyczna. Chociaż dokładna patofizjologia TED pozostaje niejasna, prawdo-
podobnie jest ona wyrazem reakcji autoimmunologicznej z udziałem uczulonych limfocytów T i przeciwciał skierowanych przeciwko
swoistym antygenom oczodołu i wspólnemu antygenowi nabłonka pęcherzykowego tarczycy i tkanek oczodołu. Jednym dobrze pozna-
nym powodem tej reakcji jest receptor hormonu stymulującego tarczycę (TSHR, thyroid-stimulating hormone receptor), którego ekspresję
stwierdzono także na fibroblastach i preadipocytach pobranych z oczodołu osób chorych. Większość pacjentów z orbitopatią choruje
także na chorobę Gravesa, 10% na zapalenie tarczycy Hashimoto z łagodnymi zmianami ocznymi wyrażonymi głównie pod postacią
retrakcji powieki górnej i 10% nie jest związana z chorobami tarczycy — tak zwana choroba Gravesa z eutyreozą. Orbitopatia może
wystąpić także u pacjentów z przejściowym zapaleniem tarczycy, rakiem tarczycy i chorobą Gravesa wiele lat po leczeniu nadczynności
— sytuacja, w której nie spodziewa się obecności przeciwciał przeciw TSHR sugeruje, że we wszystkich przypadkach związek między
przeciwciałami TSHR i chorobą oczu został wnikliwie zbadany. W niniejszym badaniu nad TED badano znaczenie przeciwciał przeciwko
innym antygenom mięśni oka i tkanki łącznej oczodołu (OCT, orbital connective tissue), a szczególnie kalsekwestrynie (CASQ1, calcium
binding protein calsequestrin), białku wiążącemu wapń i antygenowi błony oczodołowych fibroblastów, kolagenowi XIII. Powstały następu-
jące robocze hipotezy patogenezy TED: a) reakcją inicjującą w oczodole jest połączenie przeciwciała i limfocytu T z TSHR w obszarze
tkanki łącznej oczodołu; b) towarzyszące zapalenie mięśni zewnątrzoczodołowych i powieki wskazuje na reakcję autoimmunologiczną
przeciw, po pierwsze, antygenom mięśni szkieletowych, takim jak CASQ1, lub na nieswoistą reakcję tkanki łącznej oczodołu jak proponu-
je większość zwolenników „hipotezy TSHR”. W prezentowanej pracy przedstawiono dowody na to, że reakcja autoimmunologiczna
przeciwko TSHR obserwowana w obrębie oczodołu może być stwierdzona w rozwoju wszystkich przypadków TED. Chociaż istnieje
ogólnie bliska korelacja między orbitopatią i przeciwciałami TSHR jest wiele wyjątków sugerujących, że dalsze badania nad potencjalną
rolą autoimmunizacji przeciwko kalsekwerynie i kolagenowi XIII są uzasadnione. (Endokrynol Pol 2010; 61 (2): 222–227)
Słowa kluczowe: orbitopatia, receptor TSH, choroba Gravesa, mięśnie zewnątrzoczodołowe, zapalenie tarczycy Hashimoto,
choroba Gravesa z eutyrozą, autoimmunizacja
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Introduction
Ophthalmopathy is a common manifestation of Graves’
disease. The association between “poppy eyes” and
goitre was described as early as AD 1000 by the Persian
physician and philosopher Avicenna [1]. Ophthalmop-
athy is most commonly seen in patients with Graves’
hyperthyroidism where it is called “Graves’ ophthalm-
opathy” [2, 3]. However, ophthalmopathy also occurs
in a small proportion of patients with transient (sub-
acute and silent) thyroiditis [4, 5] and in about a third of
patients with progressive (Hashimoto’s) thyroiditis [6].
Two other situations where ophthalmopathy is found
in the apparent absence of TSHR antibodies are thy-
roid cancer [7] and Graves’ disease many years after
treatment of the hyperthyroidism (Wall et al., unpub-
lished observations). In about 10% of cases, the oph-
thalmopathy occurs in the apparent absence of thyroid
autoimmunity, where it is called “euthyroid Graves’
disease (EGD)” [2]. Here, we use the generic descrip-
tion of “thyroid eye disease (TED)” for all of these situ-
ations. We review the TSHR hypothesis, its strengths
and weaknesses, and attempt to provide a unified hy-
pothesis that may explain all the features of TED in all
patients.
Autoimmune nature of thyroid eye disease
Although the precise pathophysiology of TED remains
unclear it is likely to reflect an autoimmune reaction
involving sensitised T lymphocytes and autoantibod-
ies directed against specific orbital or “thyroid and or-
bital tissue shared antigen(s)”. What makes TED a con-
troversial disorder is 1) the identity of the primary
antigen(s) is unresolved, 2) it is not clear whether the
eye muscles or OCT is/are the primary target tissue in
the orbit or whether both tissues are always involved,
and 3) one must explain how the ophthalmopathy is
linked to thyroid autoimmunity. While most workers
believe that the eye disorder is due to cross reactivity
against the TSHR in the orbital tissues [8], there is grow-
ing evidence that autoimmunity against eye muscle
antigens, especially the calcium binding protein calse-
questrin (CASQ1), may also play a role in the evolution
of the disease once the eye muscle fibre has been
breached (since CASQ1 is mainly an intra cellular pro-
tein). Another possibility is that the initial reaction
is against the TSHR, which leads to orbital fibroblast
stimulation and proliferation, and that the eye muscle
damage is secondary to this.
TED has been described by one of us (JW) as a “lim-
ited multi system autoimmune disorder” involving an-
tigens in the OCT, eye muscle fibre, the lacrimal gland,
human Harderian gland equivalent, and the thyroid
gland [9]. Apart from the TSHR and CASQ1, another
putative orbital antigen is collagen XIII, a connective
tissue antigen expressed in the orbital fibroblast cell
membranes. It seems likely that the tissue reactions re-
flect multiple autoimmune targeting of these and other
antigens, possibly including nuclear proteins.
Classification of thyroid eye disease
There are three main subtypes of TED, namely: con-
gestive ophthalmopathy, ocular myopathy, and mixed
congestive and myopathic ophthalmopathy — which
is the most common. The main features and candidate
auto-antigens for each subtype are listed in Table I.
Congestive ophthalmopathy is characterised by inflam-
mation of the OCT with relative sparing of the extra
ocular muscles, presenting as eye swelling, conjuncti-
val injection, chemosis, watery or gritty eyes, and ex-
ophthalmos. In contrast, ocular myopathy is character-
ised by inflammation and swelling of the extra ocular
Table I. Thyroid eye disease subtypes, clinical features, and candidate autoantibodies
Tabela I. Podtypy orbitopatii tarczycowej, cechy kliniczne i autoprzeciwciała występujące u pacjentów
TED subtype Main clinical features Candidate auto-antigens
Ocular myopathy Diplopia Calsequestrin
EOM dysfunction G2s*
Exophthalmos Flavoprotein
Congestive ophthalmopathy Watery, gritty eyes TSHR
Periorbital oedema Collagen XIII
Conjunctival injection/chemosis
Exophthalmos
Mixed congestive and myopathic ophthalmopathy Congestive and myopathic signs/symptoms All of the above
*G2s is a fragment of the FOX-P1 transcription factor; EOM — extra ocular muscle; TSHR — thyroid-stimulating hormone receptor
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muscles and manifests as eye muscle dysfunction, diplo-
pia, and, occasionally, painful eye movement.
Although congestive and myopathic features can
occur in isolation, the most common presentation of
TED is mixed congestive and myopathic ophthalmop-
athy, half of which have UER as well, occurring in about
40% of patients with “Graves’ ophthalmopathy” [10].
In patients with Hashimoto’s thyroiditis, UER and lag
are often the only features of an ophthalmopathy, ex-
cept for mild proptosis ([6], and may represent a sepa-
rate subtype. The estimated prevalence of the three
components of TED alone and in association with one,
or the other, or both other subtypes, are summarised in
Figure 1. Overall, approximately 70% of patients with
TED (i.e. Graves’ disease or Hashimoto’s thyroiditis plus
ophthalmopathy, or EGD) have OCT inflammation,
50% have EOM involvement, and 50% have chronic
UER, which are found as isolated abnormalities in 25%,
5% and 15%, respectively of cases.
TSH-receptor hypothesis
The generally held theory for the pathogenesis of TED
is that the primary reaction involves antibodies target-
ing the TSHR expressed in the OCT, which leads to or-
bital inflammation manifesting as orbital fibroblast stim-
ulation, collagen and glycosaminoglycans (GAGS) pro-
duction, and signs and symptoms of peri orbital and
conjunctival inflammation and congestion [11]. Accord-
ing to this theory, ocular myopathy is due to ischaemic
damage to the eye muscles following a primary OCT
inflammatory reaction, i.e. it is secondary. Certainly, the
TSHR is a logical candidate antigen as it is expressed in
the orbital preadipocytes and fibroblasts (as well as the
thyroid gland) [9, 11]. While its expression in other tis-
sues such as testis, systemic fat, and skin connective tis-
sue [12, 13] could explain the development of pretibial
myxedema and thyroid acropachy as local manifesta-
tions of a generalise connective tissue disorder in
Graves’ disease, it could also be argued that the tissue
non specificity of the reactions makes a primary eye
muscle reaction more likely. Certainly, the eye muscle
fibre always seemed to us a more likely candidate auto-
antigen than the loose, fatty connective tissue in and
around the eye muscles (hence our long-standing in-
terest in the eye and eyelid muscles).
Although there is strong overall support for a key
role of the TSHR in the pathogenesis of TED, whether
or not TSHR antibodies are linked to ophthalmopathy
in all cases of TED remains unclear. For example, it
seems unlikely that TSHR antibodies can explain the
development of ophthalmopathy in patients in whom
the eye changes occur many years after the develop-
ment of Graves’ hyperthyroidism or in patients with
Hashimoto’s thyroiditis in whom eye changes occur in
the frequent absence of TSHR antibody production.
Furthermore, newborns with neonatal thyrotoxicosis do
not have ophthalmopathy even when the mother has
eye signs, and Amato et al. [14] reported the case of
a Caucasian male who developed euthyroid Graves’ dis-
ease after proven sub-acute thyroiditis in the absence
of TSHR antibodies but with detectable eye muscle an-
tibodies. Finally, as discussed above, the TSHR is also
expressed in fibroblasts and adipocytes at sites such as
the abdominal wall, which are presumed to be unaf-
fected in Graves’ disease patients [15]. However, one
cannot exclude the possibility that TSHR antibodies
were present at the onset of their eye disease in all pa-
tients with TED, including those with Hashimoto’s thy-
roiditis and EGD, but negative at the time of presenta-
tion or initial testing.
Overall, these findings do suggest that a specific link
between thyroid autoimmunity, the TSHR, and oph-
thalmopathy has not yet been proven in all situations.
In order to test the notion that autoimmunity against
TSHR can explain all cases of TED carried out a PubMed
search for the period 2005 to the present, examining all
relevant papers published during this period that ad-
dress the relationship between ophthalmopathy and
TSHR antibodies. While it is certain that some studies
have been missed, the 10 papers reviewed seem repre-
Figure 1. Proposed relationships between the three main compo-
nents of “thyroid eye disease” (extra ocular muscle (EOM) dysfun-
ction, orbital connective tissue (OCT), and fat inflammation and
upper eyelid retraction [UER]) and estimated frequencies (%) of
their associations
Rycina 1. Propoonowany związek między trzema głównymi
składowymi orbitopatii tarczycowej (dysfunkcja mięśnia
zewnętrznego oka (EOM), tkanka łączna oczodołu (OCT) i stan
zapalny tkanki tłuszczowej oraz opadanie powieki górnej (UER)
oraz szacunkowa częstoliwość współwystępowania (%)
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sentative of the total experience of workers over the past
20 years. The results are summarised in table II. While
a close general relationship between serum TSHR anti-
bodies — especially those that stimulate the TSHR, so-
called thyroid-stimulating immunoglobulin (TSI) — and
ophthalmopathy in patients with thyroid autoimmu-
nity is confirmed, this is less close for patients with EGD,
and even in Graves’ disease there are exceptions.
Euthyroid Graves’ disease
In order to further address the relationship between
ophthalmopathy and TSHR antibodies we have stud-
ied 10 patients with EGD, all of whom have been fol-
lowed for several years (range 3–7 years, median dura-
tion 4 years) with always normal TSH and fT4 levels and
negative thyroid antibodies (Wall et al., in preparation).
TSHR antibodies were not detected in any of the 4 pa-
tients tested, CASQ1 antibodies were positive in 4 of
8 patients tested, and collagen XIII antibodies were de-
tected in 2 of the 8 patients. The eye features were quan-
tified according to standard classification and nomen-
clature systems [25–27] at the first visit to the thyroid
clinics at Nepean Hospital. Clinical activity score (CAS)
ranged from 1–7 (median score 5) indicating that the
disease was active, whereas 4 patients had eye muscle
involvement (NOSPECS class 4, Nunery type 2) of
whom 3 had increased eye muscle volumes on orbital
CT imaging and 2 of the 8 patients had significant UER
(Margin-reflex distance > 5 mm). Two patients were
being treated with low doses of prednisolone at the time
of study. Interestingly, three patients had thyroid ul-
trasound abnormalities, namely follicular adenoma
(proven at surgery), goitre, and nodules, but there was
Table II. Relationship between TSH-receptor antibodies and ophthalmopathy in patients with autoimmune thyroid disease
Tabela II. Zależność między przeciwciałami przeciwko receptorowi TSH i orbitopatią u pacjentów z autoimmunologiczną
chorobą tarczycy
Group Main findings Comment Reference
Hypothyroid GO (n = 11) Mean TBII 2.2 iu/L for the TSHR Ab levels were Eckstein et al [16]
Euthyroid GO (n = 28) two groups v. 8.6 in “very low” in both groups
hyperthyroid patients with of patients. TSI was
ophthalmopathy (p = 0.02)    not measured
One case of EGD TSHR Ab negative TSI was not measured Cakir [17]
Graves’ disease before Patients with GO had TSI was not measured Massart et al. [18]
treatment  greater TSHR Ab levels than
patients with no ophthalmopathy
One patient with differentiated There was a close correlation TSI was not measured Antonelli et al. [7]
thyroid cancer who developed between eye signs and TSHR
ophthalmopathy   Ab positivity and titres
GO 65% of patients had positive TSI, Overall close positive Acuna et al. [19]
69% of whom developed correlation but many
ophthalmopathy v. 24% of those exceptions
with negative or borderline
positive tests
GO and isolated ocular 5 out of 7 patients had positive “Same TSHR Ab profile as Gerlach, Febert [20]
myopathy (n = 7), 6 of whom TBII, 1 had positive TPO Abs other patients with GO”,
had increased EOM volumes  but negative TBII except in one patient
Recurrent GO post total Mean TRAb 33.8 iu/L Close overall correlation Nart et al. [21]
thyroidectomy  v. 3.4 iu/L before and after between ophthalmopathy
total thyroidectomy   and TSHR Abs
Graves’ disease (n = 210) 92% TBII positive but titres Retrospective study Lin et al. [22]
did not correlate with severity
of ophthalmopathy
EGD (n = 35; A), GO (n = 9; B) TBII pos. in 28.6% of A TSI is more closely Kazuo et al. [23]
and TSAb pos. in 83% of B; related to EGD than TBII
in B, both pos 100%
GO (n = 482) “Thyroid dysfunction is associated A retrospective study Kim et al. [24]
with a more severe
ophthalmopathy compared
to euthyroid state”
GO — Graves’ ophthalmopathy; TBII — TSH binding inhibiting immunoglobulin; Ab — antibody; EGD — euthyroid Graves’ disease; TSI — thyroid
stimulating immunoglobulin; EOM — extra ocular muscle; TPO — thyroid peroxidase.
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no evidence for thyroid autoimmunity except for “mild
thyroiditis” in one patient (Wall et al., in preparation).
Role of autoimmunity against calsequestrin
In our earlier studies, using a crude preparation of calse-
questrin prepared from rabbit heart muscle, and by
measuring corresponding calsequestrin antibodies by
western blot analysis, we found a modest relationship
between anti-calsequestrin antibodies and ophthalm-
opathy. Anti-calsequestrin antibodies were detected in
40% of patients with clinically active TAO but only in
5% of normal subjects [28]. When Porter et al. [29]
showed that calsequestrin was expressed 4.8 times more
in eye muscle compared to other skeletal muscle, thus
offering an explanation for the orbital specificity of skel-
etal muscle inflammation in Graves’ disease, we decid-
ed to re-address its possible role in the pathogenesis of
TED. Calsequestrin seemed a good candidate as it was
shown to be distributed throughout the cell during the
myotube stage of differentiation, where it could be seen
by antibodies and T-cells. In our initial studies we de-
termined the prevalence of anti-calsequestrin antibodies
in a large group of patients with thyroid autoimmunity,
with and without ophthalmopathy, using enzyme-linked
immunosorbent assay (ELISA) incorporating highly puri-
fied rabbit skeletal muscle calsequestrin. We demonstrat-
ed that calsequestrin antibodies were good markers of
ophthalmopathy, in particular of the ocular myopathy
subtype of “Graves’ ophthalmopathy” [10, 30, 31].
Next, we set out to identify differentially expressed
genes within the thyroid of “Graves’ ophthalmopathy”
(GO) and Graves’ hyperthyroidism (without ophthal-
mopathy) (GH) patients as a possible explanation for
a thyroid-initiated orbital autoimmunity. RNA was ex-
tracted from thyroid glands of patients with Graves’
disease. RNA samples were arrayed on Illumina® Hu-
man Ref-8 Expression BeadChips™ representing
20,5193 genes, the results of selected genes were vali-
dated by quantitative PCR (qPCR), and levels of pro-
tein translation were measured by Western Blot analy-
sis. Two hundred and ninety-five genes were differen-
tially expressed between GO and GH patients. Of these,
the cardiac calsequestrin gene (CASQ2) was the most
highly expressed gene in GO (2.2-fold increase) [32]. The
succinate dehydrogenase flavoprotein subunit gene
(sdha) was also significantly up-regulated in GO
(1.4-fold) while genes encoding the thyroid antigens
thyroglobulin, thyroid peroxidase, and TSHR were not
differentially expressed between GH and GO [32]. The
skeletal and cardiac calsequestrin proteins share 68.4%
amino acid homology [33]. Previous work has shown
that RNA levels of skeletal muscle calsequestrin are
4.7 times higher in extraocular muscle than in mastica-
tory skeletal muscle [29], and that cardiac calsequestrin
is expressed 2.7 times more in extra ocular muscle [34].
From these surprising findings we postulated that up-
regulation of the CASQ2 gene in the thyroid of patients
with Graves’ disease may lead to the production of au-
toantibodies and sensitised T lymphocytes, which cross-
react with calsequestrin in the extra ocular muscle of
patients who develop ophthalmopathy.
Ophthalmopathy in patients with thyroiditis
Subacute thyroiditis (SAT) and silent thyroiditis (ST) are
the most common causes of transient thyrotoxicosis.
There have been reports of the development of TSHR
positive Graves’ hyperthyroidism and ophthalmopathy
following SAT [35, 36]. We studied the prevalence of
eye and eyelid signs and positive eye muscle and col-
lagen XIII antibody tests in 11 patients with transient
thyroiditis, 5 with SAT, and 6 with ST, and in age and
sex-matched healthy controls. Five patients with tran-
sient thyroiditis developed ophthalmopathy at the first
visit or on follow-up. TSHR antibodies were found in
only one of these patients, a 20-year-old woman who
developed Graves’ hyperthyroidism following an epi-
sode of ST, but one or more eye muscle or collagen XIII
antibodies were detected in 7 of the patients and anti-
body levels correlated generally with eye signs. Calse-
questrin and Fp antibodies were the most frequently
detected, and collagen XIII antibodies were detected in
two patients with ST [5].
More recently, we studied the prevalence and phe-
notype of ophthalmopathy in patients with Hashimo-
to’s thyroiditis, correlating eye signs with calsequestrin
and collagen XIII antibodies [6]. We showed that mild
eye changes are common in patients with Hashimoto’s
thyroiditis, and the overall prevalence of “ophthalm-
opathy” is much greater than previously thought, be-
ing present in about a third of the patients. However,
the relationship between eye signs and calsequestrin
antibodies was only modest in this study, and some
patients with positive tests did not have eye signs, which
could have reflected the long natural history of Hash-
imoto’s thyroiditis.
Risk factors for ophthalmopathy
The phenotypic variation of eye signs in patients with
TED suggests that complex interactions between endog-
enous (genetic factors, increasing age, male sex) and
exogenous (cigarette smoking, hyperthyroidism and
hypothyroidism, radioiodine treatment) factors may
influence the development and severity of ophthalm-
opathy [37]. Smoking appears to be the greatest risk fac-
tor for ophthalmopathy [38, 39], while the role of ge-
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netic factors in its development remains unclear. Re-
cent work has focused on identifying genetic alterations
associated with GO through small scale and inconclu-
sive case-controlled association studies with candidate
genes. The relationship between the autoimmune reac-
tions against the TSHR and calsequestrin and putative
genetic factors are unknown but can be addressed us-
ing traditional population studies, for example deter-
mining if there is any linkage between ophthalmopa-
thy and polymorphisms of the CASQ1, TSHR, and col-
lagen XIII genes — studies which are in progress in our
laboratory.
Conclusions
Most workers and readers accept the TSHR hypothesis
as being fact. However, the role of autoimmunity against
calsequestrin also deserves to be taken seriously. While
there is a strong overall association between TSHR Abs
and ophthalmopathy, this varies according to the test
used and patient population studied. We postulate that
while antibodies directed against TSHR may be the ini-
tiating event that leads to orbital inflammation, anti-
body and T lymphocyte reactivity against calsequestrin,
or some other eye muscle cell membrane antigen, may
separately and independently lead to eye and eyelid
muscle inflammation and damage, manifest as diplo-
pia and UER. While it is less likely that autoimmunity
against the TSHR in the OCT leads to secondary eye
muscle damage, particularly as ocular myopathy can
occur as an isolated abnormality in patients with no
OCT inflammation (or in the case of EGD, thyroid in-
flammation), this has not been excluded. Larger pro-
spective studies of well-characterised patients with thy-
roid autoimmunity with and without ophthalmopathy
and of patients with EGD long term and control pa-
tients with other muscle and eye disorders should be
carried out.
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